NASDAQ · NATRHealthcarePharmaceuticals

Nature's Sunshine Products Inc. (NATR)

$12.84+6.38%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$12.92▼ 6.04% in range
Nov 4, 2025Low $12.02 · High $27.80Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Nature's Sunshine Products closed at $12.84 on Nov 4, up 6.38%, 53.8% below its 52-week closing high. Volume of 123.2K shares was 1.23× its 20-day average (close to normal).

Split-adjusted performance: +2.4% over one month, -51.1% over six months, -6.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $116.98M, up 1.9% from a year earlier, with a net margin of 3.0%.

Short interest was 918.7K shares at the Oct 15 settlement, up 7.2% from the prior report (6.4% of float, 8.2 days to cover).

Market cap$225.9M17.6M shares
Revenue · quarter$117.0M+1.9% YoY
Diluted EPS$0.19−32.1% YoY
P/E · TTM12.5×P/S 0.5×
Net margin3.0%Gross 73.7%
Dividend yieldNone$1 last paid
52-week range12.02 – 27.80−53.8% from high
Volume123.2K1.23× 20-day avg
Volatility · 60d24.2%Annualised
Short % of float6.4%8.2 days to cover
Net cash$82.5MCash $82.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.1%1M +2.4%3M −36.9%6M −51.1%YTD −40.5%1Y −6.7%3Y −27.8%5Y −17.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum24
Revenue growth44
Net margin72
Value (low P/E)62
Size49

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short918.7K+7.2% vs prior
Days to cover8.2Settled Oct 15
% of float6.4%
Short vol. 10d63.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NATRNature's Sunshine Products$12.84+6.38%−51.1%+1.9%3.0%12.5$225.9M
SIGASIGA Technologies$3.15+1.29%−33.0%−49.5%30.4%—$226.3MCompare
ADCTADC Therapeutics SA$1.72+10.97%−55.4%+2.2%−86.1%—$219.6MCompare
ELDNEledon Pharmaceuticals$2.70+3.05%−28.9%———$219.4MCompare
EVMNEvommune$6.04+1.68%−74.7%———$219.2MCompare
VNDAVanda Pharmaceuticals$3.88+3.47%−47.8%+24.1%−32.3%—$234.6MCompare
CAMPCAMP4 Therapeutics$3.74−2.35%−7.9%+18.8%−1884.8%—$234.7MCompare
KROSKeros Therapeutics$10.830.00%−8.1%−100.0%——$214.7MCompare
GLSIGreenwich LifeSciences$16.35+2.70%−29.1%———$240.0MCompare

Quick answers

What does Nature's Sunshine Products do?
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc.
What is NATR's market cap?
$225.93M, based on the Nov 4 close of $12.84.
What is NATR's P/E ratio?
12.5× trailing-twelve-month earnings of $18.10M.
Does Nature's Sunshine Products pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NATR is sold short?
918.7K shares, 6.4% of float, as of Oct 15, 2026.
What sector is NATR in?
Healthcare, in the Pharmaceuticals industry.

About Nature's Sunshine Products

Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.

HQ: Lehi, UT806 employeesListed Aug 7, 1980natr.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology